Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | SDCBP | O00560 | 1/20 | 0.33 |
| ▸ | SDC2 | P34741 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6443647 | 1.00 | POLB (0.38) | POLBSMN1; SMN2NPSR1HPGDPPARG | |
| SCHEMBL4058277 | 0.81 | POLB (0.40) | POLBSMN1; SMN2NPSR1HPGDPPARG | |
| SCHEMBL35210732 | 0.74 | TSHR (0.43) | POLBSMN1; SMN2HPGDPPARGPPARA | |
| SCHEMBL30473771 | 0.73 | SMN1; SMN2 (0.58) | SMN1; SMN2PPARGPPARAPLA2G2APLA2G5 | |
| SCHEMBL30414898 | 0.72 | ALDH1A1 (0.38) | POLBSMN1; SMN2NPSR1HPGDPLA2G2A | |
| SCHEMBL3687552 | 0.69 | TYR (0.44) | SMN1; SMN2NPSR1PPARGPPARAPLA2G2A | |
| SCHEMBL903604 | 0.69 | TYR (0.44) | SMN1; SMN2NPSR1PPARGPPARAPLA2G2A | |
| SCHEMBL15289820 | 0.68 | SMN1; SMN2 (0.37) | SMN1; SMN2NPSR1PLA2G2APLA2G5CA12 | |
| Lactic Acid SCHEMBL1833813 | 0.68 | TP53 (0.48) | HPGDPTGER4KDM4EALDH1A1 | |
| SCHEMBL15091742 | 0.68 | SMN1; SMN2 (0.37) | SMN1; SMN2NPSR1PLA2G2APLA2G5CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | POLB 1584/4885SMN1; SMN2 1200/4885NPSR1 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.